MedPath

The Research of the Effect of Sevoflurane on Brain-protection of Cardiac Surgery in Infants.

Not Applicable
Conditions
Congenital Heart Disease
Infant, Premature, Diseases
Interventions
Registration Number
NCT03366597
Lead Sponsor
Jun Ma
Brief Summary

To observe the effect of sevoflurane on the concentration of S100β and regional cerebral oxygen saturation in infants with congenital heart disease undergoing cardiac surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Clinical diagnosis of congenital heart disease
  • Undergoing heart surgery with cardiopulmonary bypass
Exclusion Criteria
  • Pulmonary arterial hypertension
  • Sevoflurane allergy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SevofluraneSevofluraneSevoflurane will be used as a narcotic drug in one group during cardiac surgery.
Primary Outcome Measures
NameTimeMethod
Concentration of S100β protein5 minutes after tracheal intubation; immediately after cardiopulmonary bypass; immediately after operation; 12 hours, 24 hours postoperative

The concentration of S100β protein was performed using the electrochemiluminescence immunoassay.(Blood samples from patients were drawn from central intravenous.)

Secondary Outcome Measures
NameTimeMethod
Level of regional cerebral oxygen saturation(rScO2)5 minutes after tracheal intubation; immediately after cardiopulmonary bypass; immediately after operation; 12 hours, 24 hours postoperative

The rScO2 was measured by using noninvasive near-infrared spectroscopy during cardiac surgery

Trial Locations

Locations (1)

Beijing Anzhen Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath